secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001854270-25-000069
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio receives FDA Orphan Drug Designation for SENTI-202 CAR NK therapy in AML
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematologic malignancies, including AML.
- SENTI-202 is a first-in-class Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy.
- Phase 1 trial (NCT06325748) is ongoing; median survival for relapsed/refractory AML is 5.3 months.
- Designation provides tax credits, FDA fee exemptions, and potential 7-year market exclusivity.
- Approximately 20,800 new AML cases per year in the US, with 60% relapsing or dying within 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000069/0001854270-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000069/snti-20250618.htm
  HTML page:      https://secwatch.observer/filing/0001854270-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer